Company Profile

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE381.1011.9 (+3.22 % )
PREV CLOSE (Rs.) 369.20
OPEN PRICE (Rs.) 385.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1731
TODAY'S LOW / HIGH (Rs.)377.60 386.20
52 WK LOW / HIGH (Rs.)341.05 643.75
NSE381.35 11.4 (+3.08 % )
PREV CLOSE(Rs.) 369.95
OPEN PRICE (Rs.) 380.00
BID PRICE (QTY) 381.35 (50 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 129719
TODAY'S LOW / HIGH(Rs.) 377.20 388.90
52 WK LOW / HIGH (Rs.)321 644

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 6.5972
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 31.83
ROCE (%) 25.98
Incorporation Year : 2007

Management Info :

- Chairman Amit Indubhushan Bakshi - Managing Director

Registered Office :

Address : 8th Floor, Commerce House I V,Beside Shell Petrol Pump,100 Feet Road, Prahladnagar,
Ahmedabad,
Gujarat-380015

Phone : 079 3045 1111

Website : www.eris.co.in

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
11Mar03-11-2020$Eris Lifesciences informs about outcome of board meeting Eris Lifesciences informs ab

Eris Lifesciences has informed that the Board of Directors of the Company at their meeting held today, March 11, 2020 duly approved the declaration of Interim Dividend of Rs 2.87 (at the rate of 287%) on each fully paid-up equity share of Re 1 for the Financial Year 2019-20. Further informed that, the Company has fixed 20th March, 2020 as the record date to determine the names of the equity shareholders, who shall be entitled to receive the payment towards interim dividend for the financial year 2019-20. The payment of the interim dividend would be made to the eligible shareholders on or before 10th April, 2020.

The above information is a part of company’s filings submitted to BSE.

Eris Lifesciences has informed that the Board of Directors of t..
08Feb02-08-2020$Eris Lifesciences submits board meeting intimation Eris Lifesciences submits bo

Eris Lifesciences has submitted the board meeting intimation.

The above information is a part of company’s filings submitted to BSE.

Eris Lifesciences has submitted the board meeting intimation.Th..
07Feb02-07-2020$ Board Meeting Intimation for Board Meeting Intimation Board Meeting Intimation fo
Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ('the Company') is scheduled to be held on Friday, 14th February, 2020 to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended 31st December, 2019. Further, as informed by us vide letter dated 26th December, 2019, the trading window has been already closed from 1st January, 2020 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company'' for the purpose of Board Meeting.
Eris Lifesciences Ltdhas informed BSE that the meeting of the B..
27Jan01-27-2020$Eris Lifesciences informs about updates on buyback offer Eris Lifesciences informs ab

Axis Capital (Manager to Buyback Offer) has submitted a copy of post Buyback Public Announcement for the attention of the Equity Shareholders/ Beneficial Owners of Equity Shares of Eris Lifesciences (Target Company).

The above information is a part of company’s filings submitted to BSE.

Axis Capital (Manager to Buyback Offer) has submitted a copy of..
27Jan01-27-2020$ Updates on Buyback Offer Updates on Buyback Offer
Axis Capital Limited ("Manager to Buyback Offer) has submitted to BSE a copy of post Buyback Public Announcement for the attention of the Equity Shareholders / Beneficial Owners of Equity Shares of Eris Lifesciences Ltd ("Target Company").
Axis Capital Limited ("Manager to Buyback Offer) has submitted..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit626.762853.81
Gross Profit 710.06 3117.76
Operating Profit 826.943661.58
Net Sales 2542.698965.39
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 16722.05 (5.66%)
M.Cap ( in Cr)
35533.19
Procter&Gamble Healt (BSE)
 4324.60 (11.90%)
M.Cap ( in Cr)
7178.57
Dr. Reddys Lab (BSE)
 3583.15 (13.94%)
M.Cap ( in Cr)
59541.95
Sanofi India (BSE)
 7023.75 (5.40%)
M.Cap ( in Cr)
16176.13
Astrazeneca Pharma I (BSE)
 2694.10 (12.08%)
M.Cap ( in Cr)
6735.25
Shareholding Pattern More
PROMOTERS 56.23 %
NON-INSTITUTION 23.11 %
MUTUAL FUNDS/UTI 11.13 %
FI/BANKS/INSURANCE 0.02 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes